3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
44
Liver Neoplasms
18
Colorectal Neoplasms
15
Neoplasm Metastasis
11
Cholangiocarcinoma
11
Pancreatic Neoplasms
9
Colonic Neoplasms
9
Barrett Esophagus
7
Rectal Neoplasms
6
Recurrence
5
Esophageal Neoplasms
4
Biliary Tract Neoplasms
3
Bile Duct Neoplasms
3
Hepatitis B
2
Gallbladder Neoplasms
2
Stomach Neoplasms
1
Solid Tumor Including Thyroid, Bone, Liver, Pancreas
1
Pancreatic cancer, adult
1
Pancreatic Neuroendocrine Tumors, WHO Grade I-II
1
Neuroendocrine Tumors
1
Neoplastic Cells, Circulating
1
Neoplasms, Glandular and Epithelial
1
Neoplasms
1
Neoplasm Micrometastasis
1
Multi-organ Metastatic Colorectal Cancer
1
Liver Metastasis Colon Cancer
1
Klatskin Tumor
1
Jaundice, Obstructive
1
Hypertension, Portal
1
Hepatitis B, Chronic
1
Interventions
Gemcitabine
4
pembrolizumab
3
napabucasin
3
Irinotecan
3
Albumin-Bound Paclitaxel
3
130-nm albumin-bound paclitaxel
3
lenvatinib
2
entinostat
2
Taxes
2
Sunitinib
2
Sorafenib
2
Paclitaxel
2
Leucovorin
2
Fluorouracil
2
Cisplatin
2
Bevacizumab
2
pralsetinib
1
linifanib
1
durvalumab
1
Radiofrequency Ablation
1
Pemetrexed
1
Nivolumab
1
Immunotherapy
1
Endoscopic Mucosal Resection
1
Cobicistat
1
Chemoradiotherapy
1
Capecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Glandular and Epithelial
×
Radiofrequency Ablation
×
Gastrointestinal
×
Clear all
NCT02192671
2022-01-18
HR-HCC/PHT
Guangxi Medical University
Phase 3
Unknown
120 enrolled